Quick Answer
Tyra Biosciences, Inc. reported Net Income of -$119.95 million for fiscal year 2025.
Tyra Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$119.95M -38.7% |
-$86.48M -25.1% |
-$69.13M -25.0% |
-$55.33M -110.4% |
-$26.29M -181.6% |
-$9.34M |
| Diluted EPS | -$2.01 -33.1% |
-$1.51 +6.8% |
-$1.62 -22.7% |
-$1.32 +30.9% |
-$1.91 | — |
| Total Assets | $282.61M -22.3% |
$363.56M +61.0% |
$225.86M -15.1% |
$266.18M -13.2% |
$306.70M +1815.6% |
$16.01M |
| Cash and Equivalents | $77.39M -15.9% |
$91.97M +58.5% |
$58.01M -76.9% |
$251.21M -16.9% |
$302.18M +1884.9% |
$15.22M |
| Stockholders Equity | $259.18M -24.5% |
$343.15M +68.0% |
$204.26M -20.8% |
$257.83M -14.6% |
$301.74M +2312.5% |
-$13.64M -187.7% |
| R&D Expense | $102.93M +28.5% |
$80.08M +28.1% |
$62.52M +45.4% |
$43.01M +108.4% |
$20.64M +186.5% |
$7.20M |
| Operating Income | -$132.76M -27.4% |
-$104.18M -30.3% |
-$79.94M -35.7% |
-$58.93M -124.2% |
-$26.29M -182.8% |
-$9.30M |
| Shares Outstanding | 53.71M +5.8% |
50.75M +18.0% |
43.02M +1.6% |
42.35M +2.2% |
41.44M +2165.3% |
1.83M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$29.87M | -24.4% | -6.3% |
| Diluted EPS | September 30, 2025 | -$0.50 | -22.0% | -6.4% |
| Total Assets | September 30, 2025 | $301.85M | -20.7% | -6.1% |
| Cash and Equivalents | September 30, 2025 | $61.95M | -40.4% | -37.1% |
| Stockholders Equity | September 30, 2025 | $280.51M | -22.6% | -7.2% |
| R&D Expense | September 30, 2025 | $25.47M | +12.2% | +4.8% |
| Operating Income | September 30, 2025 | -$32.94M | -15.2% | -4.7% |
| Shares Outstanding | September 30, 2025 | 53.32M | +0.8% | +0.2% |
- Tyra Biosciences, Inc. reported Net Income of -$119.95 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -38.7% in Net Income compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Diluted EPS of $2.01 per share (loss) for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -33.1% in Diluted EPS compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Total Assets of $282.61 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -22.3% in Total Assets compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Cash and Equivalents of $77.39 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -15.9% in Cash and Equivalents compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Stockholders Equity of $259.18 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -24.5% in Stockholders Equity compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported R&D Expense of $102.93 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed an increase of +28.5% in R&D Expense compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Operating Income of -$132.76 million for fiscal year 2025.
- Tyra Biosciences, Inc. showed a decrease of -27.4% in Operating Income compared to the prior fiscal year.
- Tyra Biosciences, Inc. reported Shares Outstanding of 53.71 million shares for fiscal year 2025.
- Tyra Biosciences, Inc. showed an increase of +5.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: